

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

---

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 10, 2012

Sucampo Pharmaceuticals, Inc.

---

(Exact Name of Registrant as Specified in Charter)

Delaware

001-33609

30-0520478

---

(State or Other Jurisdiction  
of Incorporation)

(Commission  
File Number)

(IRS Employer  
Identification No.)

4520 East-West Highway, 3rd Floor  
Bethesda, Maryland

20814

---

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code: (301) 961-3400

---

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01. Regulation FD Disclosure.**

On September 10, 2012, Sucampo Pharmaceuticals, Inc. will meet with investors and investment bankers and make a corporate update presentation and webcast at an investor conference in New York City, NY, at the Annual Global Investment Conference being sponsored by Rodman & Renshaw that will include modifications to two slides from those slides filed on Form 8K dated September 7, 2012. The additional slides are being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.1 to this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

99.1 The modifications of the two slides to the corporate update presentation slides dated September 10, 2012.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SUCAMPO PHARMACEUTICALS, INC.

Date: September 10, 2012

By: /s/ Thomas J. Knapp

Name: Thomas J. Knapp

Title: Corporate Secretary

# Key Facts

Trading Symbol	SCMP (NASDAQ)
Corporate Headquarters	Bethesda, MD
Stock Price (9-4-2012), 52-Week Range	\$4.52, \$8.50 to \$2.96
Shares Outstanding (9-4-2012)	41.9 M (1 class of common stock)
Daily Volume (90-day average at 9-4-2012)	61,111
Market Capitalization (9-4-2012)	\$189 M
Debt (6-30-12)	\$60.4 M
Cash & Equivalents (6-30-12)	\$88.6 M
Enterprise Value	\$160.8M
YTD Total Revenue (6-30-2012)	\$31.1 M
Full-time Employees (2-29-2012)	108
Fiscal Year Ends	December 31
Accounting Firm	PricewaterhouseCoopers, LLP

# Management

**Peter Lichtlen, M.D., Ph.D., Senior Medical Officer and Vice President, European Operations**

- Sucampo AG
- ESBATech AG
- M.D. and Ph.D. (Molecular Biology) from University of Zurich

**Silvia Taylor, Senior Vice President of Investor Relations, Public Relations, and Corporate Communications**

- MedImmune
- Pfizer

**Other executive experience includes FDA/Center for Drug Evaluation and Research, Procter & Gamble and Allergan**